BioSpace News Archive

Pluristyx, Inc., and Implant Therapeutics, today announced they have entered into a manufacturing and distribution strategic alliance that offers cell therapy companies streamlined access to the next generation of safe, universal, cost-effective, “off-the-shelf” induced pluripotent stem cells (iPSCs).

Yingli Pharma US, Inc., a biotechnology company developing innovative small molecules, and The University of Texas MD Anderson Cancer Center announced a strategic alliance to advance several oncology programs from preclinical discovery through clinical development.

In the pancreas, insulin-producing beta cells are clustered with other hormone-producing endocrine cells and surrounded by pancreatic exocrine cells that secrete digestive enzymes.

Braintale, today announced that a leading journal, Intensive Care Medicine, published data from MRI-Coma and CENTER-TBI studies1 under Professor Louis Puybasset’s supervision entitled: Prognostic value of global deep white matter DTI metrics for 1-year outcome prediction in ICU traumatic brain injury patients: an MRI-COMA and CENTER-TBI combined study.

As compensation, Octagon Media Corp. will receive a payment of US$60,000 as well as 3,400,000 common shares of PharmaDrug.

According to Emergen Research, the global bioelectric medicine market size was USD 18.72 billion in 2020 and is expected to reach USD 33.38 billion in 2028 and register a revenue CAGR of 7.5% during the forecast period, 2021-2028.

According to Emergen Research, the global medical holographic imaging market size was USD 921.31 million in 2020 and is expected to reach USD 5,193.91 million in 2028 and register a revenue CAGR of 23.7% during the forecast period, 2021-2028.

Availability of advanced immunofluorescence assays kits and reagents, growing healthcare burden of chronic diseases, and increasing investments in healthcare sector are key factors driving market growth.

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of the market on January 27, 2022.

Cardiff Oncology, Inc. (Nasdaq: CRDF), today announced that company management will present and participate in one-on-one meetings at the B. Riley Securities 2022 Oncology Conference.